Companies expecting competition from Celgene multiple sclerosis candidate ozanimod just got a reprieve. The big biotech revealed that the FDA refused to accept its approval application because of “incomplete” pharmacology data. And that means more time for its future rivals to rack up sales unchallenged.
Ook interessant voor je
Reageer